

PolyU and Panmedi join hands to promote development of China's nuclear drug industry

25 August 2025 | News

With a focus on advancing the novel radioactive isotope Ac-225



The Hong Kong Polytechnic University (PolyU) has signed an agreement with Panmedi to further collaborate in the field of nuclear medicine, with a focus on advancing the novel radioactive isotope Ac-225 (ruthenium). -225).

The two sides will promote the transformation and industrialisation of scientific research achievements in key fields such as medical engineering and artificial intelligence medicine, improve the quality of medical services, and help the high-quality development of China's nuclear medicine industry.

As a scarce α nuclide in the world, Ac-225 can accurately destroy cancer cells with its precise targeted therapy capabilities, reducing side effects by 70% compared to traditional radiotherapy and improving patient survival. It has great potential in the field of cancer treatment. Previously, Tsinghua University and Panmedi made a breakthrough in the preparation of Ac-225 core technology, in order to achieve the amount of Ac-225 Production brings dawn.

To accelerate the clinical application of Ac-225, Panmedi will collaborate with PolyU and HKSH Medical Group to conduct clinical trials to explore its therapeutic potential in areas such as prostate cancer and neuroendocrine tumors, as well as promote science popularization and patient support programs for nuclear medicine technology to enhance public awareness of precision therapy.

In addition, PolyU will work with Tsinghua University, Panmedi and HKSH Medical Group to create a new nuclear medicine ecosystem, covering processes from isotope preparation, nuclear drug research and development to clinical services, and promote China's nuclear medicine industry technology.